ICON is a global provider of outsourced development services

Products and services

ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our services span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

Facts and figures

  • Financial information: Full year reported revenue for 2019 was $2.8 billion, representing an 8.1% year on year increase or 9.6% on a constant currency basis. Revenue guidance for full year 2020 is in the range of $2,972 - $3,092 million. At the end of Q2 2020 the company had a record closing backlog of $9.1 billion, an increase of 11% year on year (see Q2 earnings release).
  • Employee numbers: ICON currently has almost 15,150 employees in 94 locations in 40 countries.